This article is more than 5 years old. Information may no longer be current.
Study highlights potential of alternative anti-inflammatory agent
Click Here to Manage Email Alerts
A single postoperative injection of XG-102 was non-inferior to dexamethasone eye drops in the management of surgery-induced ocular inflammation in a phase 2 randomized, controlled trial.
The study, which was carried out at six sites in France, randomized 145 eyes of 145 patients undergoing combined anterior and posterior segment surgery, glaucoma surgery or complex posterior segment surgery into three groups, receiving XG-102 (brimapitide, Xigen) 90 µg, XG-102 900 µg or dexamethasone eye drops administered four times a day for 21 days. XG-102 was administered by subconjunctival injection at the end of surgery.
Anterior chamber cell grade and proportion of patients with cleared ocular inflammation at day 28 were assessed to evaluate efficacy in the three groups. Both XG-102 90 µg and XG-102 900 µg showed non-inferiority to dexamethasone in the ability to control inflammation. No statistically significant difference was reported in the number of adverse events, including IOP elevation. However, a higher number of events suggestive of ocular inflammation was reported in the XG-102 90 µg group. Regardless of the dose, there was no systemic passage of XG-102.
XG-102 is a peptide that selectively inhibits c-Jun N-terminal kinase, a factor involved in autoimmune and inflammatory processes. To date, this study is the first to evaluate safety and efficacy of XG-102 as an alternative to corticosteroids in the prevention and treatment of postoperative intraocular inflammation.
“These results are encouraging,” the study authors said. “XG-102 (brimapitide) may be an alternative to treatment with topical corticosteroids,” avoiding the well-known side effects of the latter, including IOP elevation. – by Michela Cimberle
Disclosure: Chiquet reports relevant financial activities with Allergan, AbbVie and Thea. Please see the study for all other authors’ relevant financial disclosures.
Collapse
Chiquet C, et al. Am J Ophthalmol. 2017;doi:10.1016/j.ajo.2016.10.012.
Click Here to Manage Email Alerts